Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SHR-1701 alone or with chemotherapy in unresectable stage III non-small cell lung cancer
CTR20201959Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Nov 2020; status: active.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20201959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201959.